Home / Current Issue / Paper 1719949
Model-Informed Precision Dosing (MIPD): The Evolution and Role of Pharmacists in Clinical Practice
Subject area: Science,Engineering and Technology · Area of research: Pharmacy Practice
DOI: 10.64388/IREV10I1-1719949
Abstract
A new paradigm in personalized medicine called Model-Informed Precision Dosing (MIPD) uses patient-specific data and statistical and mathematical models (pharmacokinetic, pharmacodynamic, population PK/PD, physiologically based PK, and Bayesian forecasting) to optimize drug dosage. By taking into consideration inter-individual differences in drug absorption, distribution, metabolism, excretion, and response, it seeks to optimize effectiveness while minimizing toxicity. With their knowledge of therapeutic drug monitoring, pharmacokinetics, drug therapy, and patient care, pharmacists are in a unique position to take the lead in the development, application, and use of MIPD in clinical settings. The history of MIPD is traced, the roles pharmacists play (and could play) in its implementation are examined, clinical evidence of its benefits is surveyed, important obstacles and enablers are discussed, and future directions for integrating MIPD more widely in healthcare are suggested.
Keywords
A new paradigm in personalized medicine called Model-Informed Precision Dosing (MIPD) uses patient-specific data and statistical and mathematical models (pharmacokinetic, pharmacodynamic, population PK/PD, physiologically based PK, and Bayesian forecasting) to optimize drug dosage. By taking into consideration inter-individual differences in drug absorption, distribution, metabolism, excretion, and response, it seeks to optimize effectiveness while minimizing toxicity. With their knowledge of therapeutic drug monitoring, pharmacokinetics, drug therapy, and patient care, pharmacists are in a unique position to take the lead in the development, application, and use of MIPD in clinical settings. The history of MIPD is traced, the roles pharmacists play (and could play) in its implementation are examined, clinical evidence of its benefits is surveyed, important obstacles and enablers are discussed, and future directions for integrating MIPD more widely in healthcare are suggested.
References
[1] Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities https://pubmed.ncbi.nlm.nih.gov/30255663/
[2] Berezowska A, Weiss J, Ulrich C, et al. Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice. British Journal of Clinical Pharmacology. https://pubmed.ncbi.nlm.nih.gov/39568428/
[3] Kluwe J, Keiser MJ, Caudle KE, et al. Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations. Clinical Pharmacology & Therapeutics. 2021. https://pubmed.ncbi.nlm.nih.gov/33068303/
[4] Recent Advances Addressing the Challenges of Precision Dosing. Clinical Pharmacology & Therapeutics. 2024. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3365?af=R
[5] From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology. Drugs. 2025. https://pubmed.ncbi.nlm.nih.gov/39939511/
[6] Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape. Drugs. 2024. https://pubmed.ncbi.nlm.nih.gov/39240531/
[7] Barriers and Facilitators for Bringing Model-Informed Precision Dosing to the Patient’s Bedside: A Systematic Review. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3510
[8] Model-informed precision dosing: State of the art and future perspectives https://www.sciencedirect.com/science/article/pii/S0169409X24002436
[9] Editorial: Model-informed drug development and precision dosing in clinical pharmacology practice https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1224980/full
[10] A continued learning approach for model‐informed precision dosing: Updating models in clinical practice https://pubmed.ncbi.nlm.nih.gov/34779144/
[11] Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis https://www.mdpi.com/1999-4923/16/10/1295
[12] Model-informed precision dosing of vancomycin in clinical practice: an intervention development study https://link.springer.com/article/10.1007/s11096-024-01822-x
How to cite this paper
@article{1719949,
author = {Rohit Sivakumar},
title = {Model-Informed Precision Dosing (MIPD): The Evolution and Role of Pharmacists in Clinical Practice},
journal = {Iconic Research And Engineering Journals},
year = {2026},
volume = {10},
number = {1},
pages = {2105-2109},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1719949.pdf},
abstract = {A new paradigm in personalized medicine called Model-Informed Precision Dosing (MIPD) uses patient-specific data and statistical and mathematical models (pharmacokinetic, pharmacodynamic, population PK/PD, physiologically based PK, and Bayesian forecasting) to optimize drug dosage. By taking into consideration inter-individual differences in drug absorption, distribution, metabolism, excretion, and response, it seeks to optimize effectiveness while minimizing toxicity. With their knowledge of therapeutic drug monitoring, pharmacokinetics, drug therapy, and patient care, pharmacists are in a unique position to take the lead in the development, application, and use of MIPD in clinical settings. The history of MIPD is traced, the roles pharmacists play (and could play) in its implementation are examined, clinical evidence of its benefits is surveyed, important obstacles and enablers are discussed, and future directions for integrating MIPD more widely in healthcare are suggested.},
keywords = {A new paradigm in personalized medicine called Model-Informed Precision Dosing (MIPD) uses patient-specific data and statistical and mathematical models (pharmacokinetic, pharmacodynamic, population PK/PD, physiologically based PK, and Bayesian forecasting) to optimize drug dosage. By taking into consideration inter-individual differences in drug absorption, distribution, metabolism, excretion, and response, it seeks to optimize effectiveness while minimizing toxicity. With their knowledge of therapeutic drug monitoring, pharmacokinetics, drug therapy, and patient care, pharmacists are in a unique position to take the lead in the development, application, and use of MIPD in clinical settings. The history of MIPD is traced, the roles pharmacists play (and could play) in its implementation are examined, clinical evidence of its benefits is surveyed, important obstacles and enablers are discussed, and future directions for integrating MIPD more widely in healthcare are suggested.},
month = {July},
doi = {https://doi.org/10.64388/IREV10I1-1719949}
}